Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer

Kevin T. Tran; Neil C. Chevli; Jay A. Messer; Waqar Haque; Andrew M. Farach; Raj Satkunasivam; Jun Zhang; Jorge Darcourt; Simon S. Lo; Shankar Siva; Edward B. Butler; Bin S. Teh

doi:10.1016/j.ctro.2023.100592

Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer

Kevin T. Tran, Neil C. Chevli, Jay A. Messer, Waqar Haque, Andrew M. Farach, Raj Satkunasivam, Jun Zhang, Jorge Darcourt, Simon S. Lo, Shankar Siva, Edward B. Butler, Bin S. Teh

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Purpose /Objectives Materials/Methods: The National Cancer Database (NCDB) was queried (2004–2017) for patients with RCC who did not have surgical resection but received definitive SBRT. Kaplan-Meier analysis with log-rank test was used to evaluate overall survival (OS). Univariable (UVA) and multivariable (MVA) analysis were conducted using cox proportional hazard models to determine prognostic factors for OS. Results: A total of 344 patients with median age 77 (IQR 70–85) were included in this study. Median BED₃ was 180 Gy (IQR 126.03–233.97). Median OS was 90 months in the highest quartile compared to 36–52 months in the lower three quartiles (p < 0.01). On UVA, the highest BED₃ quartile was a positive prognostic factor (HR 0.67, p < 0.01 CI 0.51–0.91) while age, tumor size, T-stage, metastasis, renal pelvis location, and transitional cell histology were negative factors. On MVA, the highest BED₃ quartile was remained significant (HR 0.69, p = 0.02; CI 0.49–0.95) as a positive factor, while age, metastasis were negative factors. Conclusion: Higher BED may be associated with improved OS. Prospective investigation is needed to clearly define optimal BED for SBRT used to treat RCC.

Original language	English (US)
Article number	100592
Pages (from-to)	100592
Journal	Clinical and Translational Radiation Oncology
Volume	39
DOIs	https://doi.org/10.1016/j.ctro.2023.100592
State	Published - Mar 2023

Keywords

Biologically equivalent dose
Renal cancer
SBRT
Stereotactic Body Radiotherapy

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctro.2023.100592

Cite this

Tran, K. T., Chevli, N. C., Messer, J. A., Haque, W., Farach, A. M., Satkunasivam, R., Zhang, J., Darcourt, J., Lo, S. S., Siva, S., Butler, E. B., & Teh, B. S. (2023). Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer. Clinical and Translational Radiation Oncology, 39, 100592. Article 100592. https://doi.org/10.1016/j.ctro.2023.100592

@article{59c37bfe0cfc468cb61d9b8a4337bd0d,

title = "Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer",

abstract = "Purpose /Objectives Materials/Methods: The National Cancer Database (NCDB) was queried (2004–2017) for patients with RCC who did not have surgical resection but received definitive SBRT. Kaplan-Meier analysis with log-rank test was used to evaluate overall survival (OS). Univariable (UVA) and multivariable (MVA) analysis were conducted using cox proportional hazard models to determine prognostic factors for OS. Results: A total of 344 patients with median age 77 (IQR 70–85) were included in this study. Median BED3 was 180 Gy (IQR 126.03–233.97). Median OS was 90 months in the highest quartile compared to 36–52 months in the lower three quartiles (p < 0.01). On UVA, the highest BED3 quartile was a positive prognostic factor (HR 0.67, p < 0.01 CI 0.51–0.91) while age, tumor size, T-stage, metastasis, renal pelvis location, and transitional cell histology were negative factors. On MVA, the highest BED3 quartile was remained significant (HR 0.69, p = 0.02; CI 0.49–0.95) as a positive factor, while age, metastasis were negative factors. Conclusion: Higher BED may be associated with improved OS. Prospective investigation is needed to clearly define optimal BED for SBRT used to treat RCC.",

keywords = "Biologically equivalent dose, Renal cancer, SBRT, Stereotactic Body Radiotherapy",

author = "Tran, {Kevin T.} and Chevli, {Neil C.} and Messer, {Jay A.} and Waqar Haque and Farach, {Andrew M.} and Raj Satkunasivam and Jun Zhang and Jorge Darcourt and Lo, {Simon S.} and Shankar Siva and Butler, {Edward B.} and Teh, {Bin S.}",

note = "{\textcopyright} 2023 The Authors.",

year = "2023",

month = mar,

doi = "10.1016/j.ctro.2023.100592",

language = "English (US)",

volume = "39",

pages = "100592",

journal = "Clinical and Translational Radiation Oncology",

issn = "2405-6308",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer

AU - Tran, Kevin T.

AU - Chevli, Neil C.

AU - Messer, Jay A.

AU - Haque, Waqar

AU - Farach, Andrew M.

AU - Satkunasivam, Raj

AU - Zhang, Jun

AU - Darcourt, Jorge

AU - Lo, Simon S.

AU - Siva, Shankar

AU - Butler, Edward B.

AU - Teh, Bin S.

PY - 2023/3

Y1 - 2023/3

N2 - Purpose /Objectives Materials/Methods: The National Cancer Database (NCDB) was queried (2004–2017) for patients with RCC who did not have surgical resection but received definitive SBRT. Kaplan-Meier analysis with log-rank test was used to evaluate overall survival (OS). Univariable (UVA) and multivariable (MVA) analysis were conducted using cox proportional hazard models to determine prognostic factors for OS. Results: A total of 344 patients with median age 77 (IQR 70–85) were included in this study. Median BED3 was 180 Gy (IQR 126.03–233.97). Median OS was 90 months in the highest quartile compared to 36–52 months in the lower three quartiles (p < 0.01). On UVA, the highest BED3 quartile was a positive prognostic factor (HR 0.67, p < 0.01 CI 0.51–0.91) while age, tumor size, T-stage, metastasis, renal pelvis location, and transitional cell histology were negative factors. On MVA, the highest BED3 quartile was remained significant (HR 0.69, p = 0.02; CI 0.49–0.95) as a positive factor, while age, metastasis were negative factors. Conclusion: Higher BED may be associated with improved OS. Prospective investigation is needed to clearly define optimal BED for SBRT used to treat RCC.

AB - Purpose /Objectives Materials/Methods: The National Cancer Database (NCDB) was queried (2004–2017) for patients with RCC who did not have surgical resection but received definitive SBRT. Kaplan-Meier analysis with log-rank test was used to evaluate overall survival (OS). Univariable (UVA) and multivariable (MVA) analysis were conducted using cox proportional hazard models to determine prognostic factors for OS. Results: A total of 344 patients with median age 77 (IQR 70–85) were included in this study. Median BED3 was 180 Gy (IQR 126.03–233.97). Median OS was 90 months in the highest quartile compared to 36–52 months in the lower three quartiles (p < 0.01). On UVA, the highest BED3 quartile was a positive prognostic factor (HR 0.67, p < 0.01 CI 0.51–0.91) while age, tumor size, T-stage, metastasis, renal pelvis location, and transitional cell histology were negative factors. On MVA, the highest BED3 quartile was remained significant (HR 0.69, p = 0.02; CI 0.49–0.95) as a positive factor, while age, metastasis were negative factors. Conclusion: Higher BED may be associated with improved OS. Prospective investigation is needed to clearly define optimal BED for SBRT used to treat RCC.

KW - Biologically equivalent dose

KW - Renal cancer

KW - SBRT

KW - Stereotactic Body Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85147977463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147977463&partnerID=8YFLogxK

U2 - 10.1016/j.ctro.2023.100592

DO - 10.1016/j.ctro.2023.100592

M3 - Article

C2 - 36935857

AN - SCOPUS:85147977463

SN - 2405-6308

VL - 39

SP - 100592

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

M1 - 100592

ER -

Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this